Navigation Links
Einstein College of Medicine receives $5.7 million for developmental disabilities research
Date:10/17/2011

October 17, 2011 (BRONX, NY) The Eunice Kennedy Shriver National Institute for Child Health and Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University $5.7 million to fund the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (IDDRC). The grant supports Einstein's ongoing efforts to improve the lives of children with intellectual and developmental disabilities (IDD) through combined basic science research and clinical practice.

Occurring in an estimated 10 percent of the population, IDDs constitute some of the most significant health conditions in children. They represent a diverse group of chronic conditions such as autism spectrum disorders and Down syndrome that can limit daily function and impede mobility, language and more. IDDs can begin anytime during a child's development up to 22 years of age, and usually last a lifetime.

"The Rose F. Kennedy Center was founded more than 40 years ago as one of the nation's flagship centers on mental retardation," said Steven Walkley, D.V.M., Ph.D., director of Einstein's IDDRC and professor in the Dominick P. Purpura Department of Neuroscience. "This grant allows us to intensify the translational research we've been doing, which when coupled with clinical care, may lead to a better understanding of the causes, consequences and potential treatments of these conditions." Dr. Walkley is also professor of pathology and in the Saul R. Korey Department of Neurology. John Foxe, Ph.D., director of research at Einstein's Children's Evaluation and Rehabilitation Center (CERC), will serve as the center's associate director.

Einstein's IDDRC is an interdisciplinary collaboration involving numerous academic departments including neuroscience, genetics, neurology and pediatrics along with the Gruss Magnetic Resonance Research Center and CERC, which is directed by Robert Marion, M.D., the Ruth L. Gottesman Professor of Developmental Pediatrics. Its six scientific cores are designed to provide the means for human and animal phenotyping, neuron and whole brain imaging, cell and tissue manipulation, and genetic analysis.

There will be four main areas of focus for the IDDRC that draw on Einstein's strengths in basic science research and extensive clinical practice. The themes are autism spectrum disorders, neurogenetic and seizure disorders, nutritional and environmental determinants of brain development, and deafness and communication disorders.

"While tremendous strides have been made over the past four decades to identify and treat these disorders, it is critical to leverage the most recent advances in research and technologies to better understand what causes them and provide more targeted and effective therapies," explained Dr. Walkley. "Through the combined efforts of our faculty researchers and clinicians, we hope to improve methods of diagnosis, prevention and treatment."

Einstein's IDDRC will also continue to build and sustain outreach programs to help alleviate some of the burden of IDDs on families in the Bronx, which is one of the most ethnically diverse and poorest urban counties in the United States.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
2. Einstein scientists find crucial molecule involved in spread of breast cancer
3. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
4. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
5. Feinstein scientists identify abnormal disease pathway in dystonia
6. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
7. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
8. ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA
9. Feinstein Institute to share $5M US Department of Defense grant
10. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
11. Einstein awarded NIH grant to study drug-resistant TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: